Cytomegalovirus infection in solid organ transplantation.

[1]  R. Razonable,et al.  New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation , 2010, Drugs.

[2]  D. Navarro,et al.  GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. , 2011, Enfermedades infecciosas y microbiologia clinica.

[3]  F. Baldanti,et al.  Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. , 2011, The new microbiologica.

[4]  C. Solano,et al.  Comparative Evaluation of Three Automated Systems for DNA Extraction in Conjunction with Three Commercially Available Real-Time PCR Assays for Quantitation of Plasma Cytomegalovirus DNAemia in Allogeneic Stem Cell Transplant Recipients , 2011, Journal of Clinical Microbiology.

[5]  M. Boeckh,et al.  Risk factors for late‐onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  H. Einsele,et al.  Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. , 2011, The Lancet. Infectious diseases.

[7]  S. Chou,et al.  Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  R. Stratta,et al.  Defining the Risks for Cytomegalovirus Infection and Disease After Solid Organ Transplantation , 2010, Pharmacotherapy.

[9]  Angela M Caliendo,et al.  International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. , 2010, Transplantation.

[10]  J. Morales,et al.  Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas–kidney transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  M. Schleiss.  VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. , 2009, Current opinion in molecular therapeutics.

[12]  Eun Jung Lee,et al.  Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Pastor,et al.  A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV‐Seropositive Lung Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  A. Åsberg,et al.  Long‐Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  Lawrence Corey,et al.  Vaccine prevention of maternal cytomegalovirus infection. , 2009, The New England journal of medicine.

[16]  Rajiv Khanna,et al.  Immunobiology of Human Cytomegalovirus: from Bench to Bedside , 2009, Clinical Microbiology Reviews.

[17]  G. Bou,et al.  Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Solano,et al.  Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2008, Journal of Clinical Microbiology.

[19]  A. Neumann,et al.  Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Y. Baez,et al.  Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. , 2008, Transplantation proceedings.

[21]  H Rollag,et al.  Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  A. Limaye,et al.  Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Pumarola,et al.  The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections , 2007, Transplantation.

[24]  V. Emery,et al.  Cytomegalovirus in transplantation – challenging the status quo , 2007, Clinical transplantation.

[25]  O. Manuel,et al.  Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. , 2007, Transplantation.

[26]  T. F. Smith,et al.  Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing , 2006, Clinical Microbiology Reviews.

[27]  J. Stoner,et al.  Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients , 2005, Annals of Internal Medicine.

[28]  G. Boivin,et al.  Human Cytomegalovirus Resistance to Antiviral Drugs , 2005, Antimicrobial Agents and Chemotherapy.

[29]  G. Snell,et al.  Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. , 2004, The Journal of infectious diseases.

[30]  B. Alexander,et al.  Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  R. Busuttil,et al.  Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients , 2003, Transplantation.

[32]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[33]  E. Mylonakis,et al.  Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Preiksaitis,et al.  The risk of transfusion‐acquired CMV infection in seronegative solid‐organ transplant recipients receiving non‐WBC‐reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center , 2002, Transfusion.

[36]  F. Prósper,et al.  Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation , 2001, Journal of Clinical Microbiology.

[37]  S. Hunt,et al.  IMPACT OF CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN ON OUTCOME AFTER CARDIOTHORACIC TRANSPLANTATION: A Comparative Study of Combined Prophylaxis with CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone , 2001, Transplantation.

[38]  D. Snydman,et al.  Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  M. Giral,et al.  Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. , 2001, Journal of the American Society of Nephrology : JASN.

[40]  D. Mclone.  The Risk , 2001, Pediatric Neurosurgery.

[41]  H. Rollag,et al.  A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1 , 2000, Transplantation.

[42]  P. Griffiths,et al.  Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[44]  J. Wetzels,et al.  The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[45]  I. Sia,et al.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. , 2000, Clinical microbiology reviews.

[46]  J. Squifflet,et al.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.

[47]  J. Aguado,et al.  [Prospective study of cytomegalovirus infection in liver transplant recipients]. , 1992, Medicina clinica.

[48]  D. Grant.  Intestinal transplantation: current status. , 1989, Transplantation proceedings.

[49]  R. Bevan,et al.  Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. , 1988, Reviews of infectious diseases.

[50]  W. V. van Son,et al.  Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes , 1988, Journal of medical virology.

[51]  H. Friedman,et al.  TOWNE-VACCINE-INDUCED PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTS , 1984, The Lancet.